ReviewFrontiers in immunology2020
Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.Annals of the rheumatic diseases · 2024Guideline
- Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.JAMA dermatology · 2026Trial
- Obesity, Low-Grade Chronic Inflammation, and Clinical Outcomes in Spondyloarthritis: A Translational Synthesis.Metabolites · 2026Review
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.Nature reviews. Rheumatology · 2026Review
- Recent Insights Into Circulating Adipokines in Obesity: Systematic Review and Meta-Analysis.Obesity science & practice · 2026Review
- Impact of dynamic changes in pain on cardiovascular disease in Chinese middle and elderly people: results from China Health and Retirement Longitudinal Study (CHARLS).BMC public health · 2025Article
- Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation.Metabolites · 2025Review
- Refractory psoriatic arthritis: emerging concepts in whole process management.Clinical rheumatology · 2025Review
- The Interplay Between Adipokines and Body Composition in Obesity and Metabolic Diseases.Cureus · 2025Review
- Hormonal Imbalance in Obesity and Arthritis: Points of Contact.Current rheumatology reviews · 2025Review
- Primary cilia and inflammatory response: unveiling new mechanisms in osteoarthritis progression.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Central obesity in psoriatic arthritis: associations with disease activity, function, and quality of life in a real-world cohort.Frontiers in medicine · 2025Article
- Macrophage Functions in Psoriasis: Lessons from Mouse Models.International journal of molecular sciences · 2024Review
- Obesity in Hypertensive Patients Is Characterized by a Dawn Phenomenon in Systolic Blood Pressure Values and Variability.Journal of clinical medicine · 2024Article
- An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis.Medicina (Kaunas, Lithuania) · 2023Observational
- Association of inflammatory biomarkers and disease activity with subclinical myocardial dysfunction in psoriatic arthritis.Scientific reports · 2023Article
- Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.Frontiers in immunology · 2023Review
- Observational
- Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multi‑center study.Rheumatology international · 2022 · on this mapArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic arthritis is a chronic inflammatory disease with skin and joint pathology as the dominant characteristics. Scientific evidence supports its systemic nature and relevant relationship with obesity, metabolic syndrome, and associated conditions. Metabolic syndrome and obesity share common signaling pathways with joint inflammation, reinforcing the idea that adipose tissue is a major contributor to disease development and severity. The adipose tissue is not a mere energy store but also an endocrine organ participating in the immune response. In the search for the best therapeutic strategy for a patient, we should appraise the adipose tissue as an endocrine and immune organ responsible for mild chronic inflammation. Today, our challenge is not only to achieve disease remission but to control the associated comorbidities as well. In light of the high prevalence of obesity in psoriatic arthritis patients and the importance of the adipose tissue in the development of chronic inflammation, we aimed to identify the most relevant articles in this regard published in English until June 2020 using the PubMed database. Search terms included psoriatic arthritis, in combination with metabolic syndrome, obesity, adipokines, cardiovascular disease, and treatment. This review summarizes the current evidence regarding the role of adipose tissue as an adipokine-secreting endocrine organ, discussing its influence on disease development and severity, and ultimately in meeting successful disease management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.